Structural and Functional Characterization of a Complex between the Acidic Transactivation Domain of EBNA2 and the Tfb1/p62 Subunit of TFIIH

English version České info

Infection with the Epstein-Barr virus (EBV) is linked to a number of human diseases and the nuclear antigen EBNA2 is one of nine viral latent proteins that plays a key role in EBV-linked diseases. EBNA2 activates expression of both viral and host gene in part through interaction between its C-terminal acidic transactivation domain (TAD) and a number of host transcriptional regulatory proteins including the general transcription factor IIH (TFIIH) and the histone acetyltransferase CBP/p300. In this manuscript, we demonstrate that the TAD of EBNA2 binds to the pleckstrin homology (PH) domain from the Tfb1/p62 subunit of TFIIH and determine a three-dimensional structure of a complex between EBNA2 and Tfb1/p62. The structure shows that three hydrophobic residues from the TAD of EBNA2 make key interactions at the complex interface and these same residues also play an important role in the binding to CBP/p300. Comparison of the structure of the EBNA2-Tfb1 complex with complexes containing acidic TADs from other proteins (p53 and VP16) bound to the same Tfb1/p62 target highlights the inherent versatility of these intrinsically disordered domains and how minor variations in positioning of key hydrophobic residues allows them to bind to common targets using different functional interfaces.

Vyšlo v časopise: Structural and Functional Characterization of a Complex between the Acidic Transactivation Domain of EBNA2 and the Tfb1/p62 Subunit of TFIIH. PLoS Pathog 10(3): e32767. doi:10.1371/journal.ppat.1004042
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004042

Souhrn

Zdroje

1. LuzuriagaK, SullivanJL (2010) Infectious mononucleosis. N Engl J Med 362 : 1993–2000.

2. NiedermanJC, MillerG, PearsonHA, PaganoJS, DowalibyJM (1976) Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med 294 : 1355–1359.

3. Shannon-LoweC, AdlandE, BellAI, DelecluseHJ, RickinsonAB, et al. (2009) Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol 83 : 7749–7760.

4. CordierM, CalenderA, BillaudM, ZimberU, RousseletG, et al. (1990) Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 64 : 1002–1013.

5. BabcockGJ, DeckerLL, VolkM, Thorley-LawsonDA (1998) EBV persistence in memory B cells in vivo. Immunity 9 : 395–404.

6. HerbstH, DallenbachF, HummelM, NiedobitekG, PileriS, et al. (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A 88 : 4766–4770.

7. JohanssonB, KleinG, HenleW, HenleG (1970) Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer 6 : 450–462.

8. RoweDT, RoweM, EvanGI, WallaceLE, FarrellPJ, et al. (1986) Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5 : 2599–2607.

9. EpsteinMA, AchongBG, BarrYM (1964) Virsu particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1 : 702–703.

10. FahraeusR, FuHL, ErnbergI, FinkeJ, RoweM, et al. (1988) Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42 : 329–338.

11. YoungLS, DawsonCW, ClarkD, RupaniH, BussonP, et al. (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69(Pt 5): 1051–1065.

12. BabcockGJ, DeckerLL, FreemanRB, Thorley-LawsonDA (1999) Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190 : 567–576.

13. HoM, MillerG, AtchisonRW, BreinigMK, DummerJS, et al. (1985) Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152 : 876–886.

14. KutokJL, WangF (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1 : 375–404.

15. WangF, GregoryC, SampleC, RoweM, LiebowitzD, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64 : 2309–2318.

16. CohenJI, WangF, MannickJ, KieffE (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86 : 9558–9562.

17. TomkinsonB, RobertsonE, KieffE (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67 : 2014–2025.

18. KayeKM, IzumiKM, KieffE (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90 : 9150–9154.

19. MannickJB, CohenJI, BirkenbachM, MarchiniA, KieffE (1991) The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 65 : 6826–6837.

20. AbbotSD, RoweM, CadwalladerK, RickstenA, GordonJ, et al. (1990) Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol 64 : 2126–2134.

21. FahraeusR, JanssonA, RickstenA, SjoblomA, RymoL (1990) Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A 87 : 7390–7394.

22. WangF, TsangSF, KurillaMG, CohenJI, KieffE (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64 : 3407–3416.

23. WoisetschlaegerM, JinXW, YandavaCN, FurmanskiLA, StromingerJL, et al. (1991) Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A 88 : 3942–3946.

24. HammerschmidtW, SugdenB (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340 : 393–397.

25. LingPD, RawlinsDR, HaywardSD (1993) The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci U S A 90 : 9237–9241.

26. GrossmanSR, JohannsenE, TongX, YalamanchiliR, KieffE (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91 : 7568–7572.

27. HenkelT, LingPD, HaywardSD, PetersonMG (1994) Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265 : 92–95.

28. WaltzerL, LogeatF, BrouC, IsraelA, SergeantA, et al. (1994) The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J 13 : 5633–5638.

29. Zimber-StroblU, StroblLJ, MeitingerC, HinrichsR, SakaiT, et al. (1994) Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J 13 : 4973–4982.

30. SungNS, KenneyS, GutschD, PaganoJS (1991) EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol 65 : 2164–2169.

31. FahraeusR, JanssonA, SjoblomA, NilssonT, KleinG, et al. (1993) Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences. Virology 195 : 71–80.

32. TsangSF, WangF, IzumiKM, KieffE (1991) Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol 65 : 6765–6771.

33. TongX, DrapkinR, ReinbergD, KieffE (1995) The 62 -⁠ and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A 92 : 3259–3263.

34. TongX, DrapkinR, YalamanchiliR, MosialosG, KieffE (1995) The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol 15 : 4735–4744.

35. TongX, WangF, ThutCJ, KieffE (1995) The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol 69 : 585–588.

36. CohenJI, KieffE (1991) An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol 65 : 5880–5885.

37. CohenJI, WangF, KieffE (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65 : 2545–2554.

38. WangL, GrossmanSR, KieffE (2000) Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A 97 : 430–435.

39. Di LelloP, NguyenBD, JonesTN, PotempaK, KoborMS, et al. (2005) NMR structure of the amino-terminal domain from the Tfb1 subunit of TFIIH and characterization of its phosphoinositide and VP16 binding sites. Biochemistry 44 : 7678–7686.

40. Di LelloP, JenkinsLM, JonesTN, NguyenBD, HaraT, et al. (2006) Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell 22 : 731–740.

41. LangloisC, MasC, Di LelloP, JenkinsLM, LegaultP, et al. (2008) NMR structure of the complex between the Tfb1 subunit of TFIIH and the activation domain of VP16: structural similarities between VP16 and p53. J Am Chem Soc 130 : 10596–10604.

42. Di LelloP, Miller JenkinsLM, MasC, LangloisC, MalitskayaE, et al. (2008) p53 and TFIIEalpha share a common binding site on the Tfb1/p62 subunit of TFIIH. Proc Natl Acad Sci U S A 105 : 106–111.

43. FerreonJC, LeeCW, AraiM, Martinez-YamoutMA, DysonHJ, et al. (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc Natl Acad Sci U S A 106 : 6591–6596.

44. TeufelDP, FreundSM, BycroftM, FershtAR (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci U S A 104 : 7009–7014.

45. CohenJI (1992) A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A 89 : 8030–8034.

46. XiaoH, PearsonA, CoulombeB, TruantR, ZhangS, et al. (1994) Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 14 : 7013–7024.

47. PearsonA, GreenblattJ (1997) Modular organization of the E2F1 activation domain and its interaction with general transcription factors TBP and TFIIH. Oncogene 15 : 2643–2658.

48. MahantaSK, SchollT, YangFC, StromingerJL (1997) Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci U S A 94 : 6324–6329.

49. KimYK, BourgeoisCF, PearsonR, TyagiM, WestMJ, et al. (2006) Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J 25 : 3596–3604.

50. RegierJL, ShenF, TriezenbergSJ (1993) Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator. Proc Natl Acad Sci U S A 90 : 883–887.

51. BlairWS, BogerdHP, MadoreSJ, CullenBR (1994) Mutational analysis of the transcription activation domain of RelA: identification of a highly synergistic minimal acidic activation module. Mol Cell Biol 14 : 7226–7234.

52. Huyghues-DespointesBM, ScholtzJM, BaldwinRL (1993) Effect of a single aspartate on helix stability at different positions in a neutral alanine-based peptide. Protein Sci 2 : 1604–1611.

53. ScholtzJM, QianH, RobbinsVH, BaldwinRL (1993) The energetics of ion-pair and hydrogen-bonding interactions in a helical peptide. Biochemistry 32 : 9668–9676.

54. Ausubel FM BR, Kingston RE, Moore DD, Smith JA, Struhl K (1997) Current Protocols in Molecular Biology (Wiley, New York).

55. LangloisC, Del GattoA, ArseneaultG, Lafrance-VanasseJ, De SimoneM, et al. (2012) Structure-based design of a potent artificial transactivation domain based on p53. J Am Chem Soc 134 : 1715–1723.

56. HoutmanJC, HigashimotoY, DimasiN, ChoS, YamaguchiH, et al. (2004) Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry 43 : 4170–4178.

57. NguyenBD, Di LelloP, LegaultP, OmichinskiJG (2005) 1H, 15N, and 13C resonance assignment of the amino-terminal domain of the Tfb1 subunit of yeast TFIIH. J Biomol NMR 31 : 173–174.

58. PascalSM, MuhandiramDR, YamazakiT, Forman-KayJD, KayLE (1994) Simultaneous acquisition of 15N -⁠ and 13C-edited NOE spectra of proteins dissolved in H2O. J Magn Reson A 197–201.

59. ZhangO, KayLE, OlivierJP, Forman-KayJD (1994) Backbone 1H and 15N resonance assignments of the N-terminal SH3 domain of drk in folded and unfolded states using enhanced-sensitivity pulsed field gradient NMR techniques. J Biomol NMR 4 : 845–858.

60. DelaglioF, GrzesiekS, VuisterGW, ZhuG, PfeiferJ, et al. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6 : 277–293.

61. VrankenWF, BoucherW, StevensTJ, FoghRH, PajonA, et al. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59 : 687–696.

62. FletcherCM, JonesDN, DiamondR, NeuhausD (1996) Treatment of NOE constraints involving equivalent or nonstereoassigned protons in calculations of biomacromolecular structures. J Biomol NMR 8 : 292–310.

63. ShenY, BaxA (2013) Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. J Biomol NMR 56 : 227–241.

64. BrungerAT, AdamsPD, CloreGM, DeLanoWL, GrosP, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54 : 905–921.

65. LaskowskiRA, RullmannnJA, MacArthurMW, KapteinR, ThorntonJM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8 : 477–486.

66. KoradiR, BilleterM, WuthrichK (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14 : 51–55, 29–32.

67. The PyMOL Molecular Graphics System. Version 1.5.0.4. Schrödinger. LLC.